Biotech Values

[DewDiligence]

After contemplating yesterday’s CC and the write-up in the Triangle Business Journal (#msg-13986203), I sold my few remaining shares of ADH. I think management is in denial—or worse—in characterizing GSK’s non-exercise of the ADH-1 option as positive. (The latest soundbite is that the ADH-1 “upside is now uncapped.”) As a result, I no longer have confidence in management’s assertions.

Good luck to those still holding. I hope it works out.